MediBeacon
Germany - MannheimBiotechnology
Focus: MediBeacon is a German biotech focused on proprietary fluorescent tracer agents and transdermal detection systems, primarily targeting nephrology and immunology indications. The company operates at mid-cap biotech scale (201–500 employees) with a clinical-stage pipeline anchored in kidney disease diagnostics and monitoring.
Profile data last refreshed 12h ago · AI intelligence enriched 3w ago
Employees
201-500
Open Jobs
0
About MediBeacon
AI assessmentNot HiringNo open roles listed right now. Follow MediBeacon to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from MediBeacon's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
3/9 — Basic
Company HealthStrong
Pipeline
Late-stage
3 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Lumitrace
Glomerular Filtration RateClinical Trials (1)
NCT07335614Evaluation of Protein Loading on Measurement of Renal Reserve
N/AHelp build intelligence for MediBeacon
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.